UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Anti-CD38 Antibody Therapy in Multiple Myeloma

Cells (Basel, Switzerland), 2019-12, Vol.8 (12), p.1629

2019

Volltextzugriff (PDF)

Proteasome inhibitors for the treatment of multiple myeloma

Expert opinion on pharmacotherapy, 2018-03, Vol.19 (4), p.375-386

2018

Volltextzugriff (PDF)

PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count

Journal of thrombosis and thrombolysis, 2020-04, Vol.49 (3), p.426-430

2020

Volltextzugriff (PDF)

Biventricular assessment of light-chain amyloidosis using 3D speckle tracking echocardiography: Differentiation from other forms of myocardial hypertrophy

International journal of cardiology, 2018-11, Vol.271, p.371-377

2018

Volltextzugriff (PDF)

Monoclonal antibodies in multiple myeloma

Panminerva medica, 2021-03, Vol.63 (1)

2021

Volltextzugriff (PDF)

Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group

Annals of hematology, 2021-04, Vol.100 (4), p.1059-1063

2021

Volltextzugriff (PDF)

Dataset on the use of 3D speckle tracking echocardiography in light-chain amyloidosis

Data in brief, 2018-06, Vol.18, p.1239-1246

2018

Volltextzugriff (PDF)

Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results

International journal of hematology, 2009-11, Vol.90 (4), p.486-491

2009

Volltextzugriff (PDF)

Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events

Blood, 2022-11, Vol.140 (Supplement 1), p.9691-9692

2022

Volltextzugriff (PDF)

Multiparameter flow cytometry (MFC) and next generation sequencing (NGS) for minimal residual disease (MRD) evaluation: Results of the FORTE trial in newly diagnosed multiple myeloma (MM)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.8533-8533

2020

Volltextzugriff (PDF)

Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study

Leukemia & lymphoma, 2017-11, Vol.58 (11), p.2738-2740

2017

Volltextzugriff (PDF)

Immunotherapy in Multiple Myeloma: Experience of the Multiple Myeloma Gimema Lazio Group

Blood, 2018-11, Vol.132 (Supplement 1), p.5634-5634

2018

Volltextzugriff (PDF)

Incidence of Severe (≤ 10g/dl) Chronic Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib and Role of Erythropoietin Therapy

Blood, 2016-12, Vol.128 (22), p.1903-1903

2016

Volltextzugriff (PDF)

Posterior Reversible Encephalopathy Syndrome (PRES) in Multiple Myeloma

Journal of case reports, 2020-09, p.201-204

2020

Volltextzugriff (PDF)

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Blood, 2019-11, Vol.134 (Supplement_1), p.5555-5555

2019

Volltextzugriff (PDF)

Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response

Leukemia & lymphoma, 2016-01, Vol.57 (1), p.99-102

2016

Volltextzugriff (PDF)

Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment

Blood, 2016-12, Vol.128 (22), p.5544-5544

2016

Volltextzugriff (PDF)

Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?

European journal of haematology, 2018-11, Vol.101 (5), p.578-584

2018

Volltextzugriff (PDF)

Event-Free Survival According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, the Worse?

Blood, 2015-12, Vol.126 (23), p.4038-4038

2015

Volltextzugriff (PDF)

Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib

American journal of hematology, 2015-02, Vol.90 (2), p.105-108

2015

Volltextzugriff (PDF)

Impact of exclusion criteria for the DASISION and ENESTnd trials in the front‐line treatment of a ‘real‐life’ patient population with chronic myeloid leukaemia

Hematological oncology, 2017-06, Vol.35 (2), p.232-236

2017

Volltextzugriff (PDF)

Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib

Oncology research and treatment, 2019-12, Vol.42 (12), p.660-664

2019

Volltextzugriff (PDF)

“Real-life” results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia

Leukemia research, 2010-11, Vol.34 (11), p.1472-1475

2010

Volltextzugriff (PDF)

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(49)
Berichte
(3)

Sprache

Englisch
(52)

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Life Sciences & Biomedicine
(21)
Humans
(19)
Female
(17)
Hematology
(15)
Aged
(14)
Male
(14)
Middle Aged
(14)
Oncology
(12)
Adult
(9)
Treatment Outcome
(8)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(6)
Aged, 80 And Over
(5)
Imatinib
(5)
Medicine
(5)
Medicine & Public Health
(5)
Remission Induction
(5)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Chronic Myeloid Leukemia
(4)
Multiple Myeloma
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Anti-CD38 Antibody Therapy in Multiple Myeloma

Proteasome inhibitors for the treatment of multiple myeloma

PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count

Biventricular assessment of light-chain amyloidosis using 3D speckle tracking echocardiography: Differentiation from other forms of myocardial hypertrophy

Monoclonal antibodies in multiple myeloma

Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group

Dataset on the use of 3D speckle tracking echocardiography in light-chain amyloidosis

Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results

Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events

Multiparameter flow cytometry (MFC) and next generation sequencing (NGS) for minimal residual disease (MRD) evaluation: Results of the FORTE trial in newly diagnosed multiple myeloma (MM)

Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study

Immunotherapy in Multiple Myeloma: Experience of the Multiple Myeloma Gimema Lazio Group

Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients

Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients

Incidence of Severe (≤ 10g/dl) Chronic Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib and Role of Erythropoietin Therapy

Posterior Reversible Encephalopathy Syndrome (PRES) in Multiple Myeloma

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response

Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment

Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?

Event-Free Survival According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, the Worse?

Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib

Impact of exclusion criteria for the DASISION and ENESTnd trials in the front‐line treatment of a ‘real‐life’ patient population with chronic myeloid leukaemia

Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib

“Real-life” results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia

Suchergebnisse filtern